Skip to main content
Premium Trial:

Request an Annual Quote

BD to Use Luminex xMAP Platform for Early-Stage Cancer Tests

NEW YORK (GenomeWeb News) – Luminex and Becton Dickinson’s Diagnostics-TriPath division have struck a development and supply agreement for biomarker-based cancer tests, Luminex said yesterday.
BD Diagnostics-TriPath will use Luminex’s multiplexing xMAP Technology, which allows multiple, simultaneous tests to be conducted using one sample, to develop diagnostic tests for certain cancers that BD will market.
Luminex said that BD plans to expand its cancer test program to include “a broad menu” of new diagnostic tests for solid tumor cancers using Luminex’s xMAP Technology.
"We believe providing biomarker testing in a multiplex format would allow detection of cancer at an earlier stage,” which could lead to better patient outcomes, BD Diagnostics-TriPath VP and GM Wayne Brinster said in a statement.
This morning at the UBS Global Life Sciences Conference in New York, Luminex CEO Patrick Balthrop said he views the agreement with BD, a leader in the flow cytometry market, as a validation of the flow-cytometry-based xMAP platform.
Balthrop did not disclose the specific cancers that would be targeted in the collaboration, but said that they would be those that are “most difficult to diagnose.”

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.